14 Papers
19 Citations
Lisa Ta is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 7, co-authored 9 publications. Previous affiliations of Lisa Ta include Semel Institute for Neuroscience and Human Behavior.
Chat about Author
Papers
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma
Wilson X. Mai,Laura Gosa,Veerle W. Daniels,Lisa Ta,Jonathan Tsang,Brian Higgins,W Blake Gilmore,Nicholas Bayley,Mitra Dehghan Harati,Jason T. Lee,William H. Yong,Harley I. Kornblum,Steven J. Bensinger,Paul S. Mischel,P. Nagesh Rao,Peter M. Clark,Timothy F. Cloughesy,Anthony Letai,David Nathanson +18 more
TL;DR: It is shown that although acute inhibition of EGFR-driven glucose metabolism induces only minimal cell death, it lowers the apoptotic threshold in a subset of patient-derived glioblastoma (GBM) cells.
Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.
David Nathanson,Amanda L. Armijo,Michelle Tom,Zheng Li,Elizabeth Dimitrova,Wayne R. Austin,Julian Nomme,Dean O. Campbell,Lisa Ta,Thuc Le,Jason T. Lee,Ryan Darvish,Ari Gordin,Liu Wei,Hsiang I. Liao,Moses Q. Wilks,Colette Martin,Saman Sadeghi,Jennifer M. Murphy,Nidal Boulos,Michael E. Phelps,Kym F. Faull,Harvey R. Herschman,Michael E. Jung,Johannes Czernin,Arnon Lavie,Caius G. Radu +26 more
TL;DR: Co-targeting of both de novo and salvage pathways for dCTP biosynthesis shows efficacy in T-ALL and B-ALL.
Biosafety and Biohazards: Understanding Biosafety Levels and Meeting Safety Requirements of a Biobank
TL;DR: The main distinctions between BSL levels are addressed including briefly introducing hazards characteristics that classify biohazardous agents, as well as define the essentials in meeting safety requirements.
Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma
Dan R. Laks,Lisa Ta,Thomas J. Crisman,Fuying Gao,Giovanni Coppola,Caius G. Radu,David Nathanson,Harley I. Kornblum +7 more
TL;DR: It is demonstrated that this combinatorial therapy elicits a differential response across a spectrum of human patient–derived glioblastoma cultures, indicating that, in the subset of sensitive gliOBlastoma, BTSCs are targeted by inhibition of pyrimidine synthesis.
Processing of Primary Patient Tumors and Subsequent Generation of Primary Cell Lines.
TL;DR: A detailed protocol on how to process and disassociate patient glioma tissue and subsequent steps on orthotopic implantation and in vitro generation of neurospheres is described.
5